Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Gunilla Enblad

Uppsala, C, SE 
Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Uppsala, C, SE 
OverviewLocationsClinical Research

Overview

Gunilla Enblad practices in Uppsala, Sweden. Enblad is rated as an Experienced expert by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Their top areas of expertise are B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Splenectomy, and Kidney Transplant.

Their clinical research consists of co-authoring 128 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Primary Mediastinal B-Cell Lymphoma (PMBCL).

Locations

Uppsala, C, Sweden
Other Locations
Eskilstuna, D, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - a Phase II Trial.
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - a Phase II Trial.
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Biological
Study Drug: CD19-Targeted CAR-T Cells
Study Phase: Phase 2
Follow-up of Malignancies in Transplanted Patients
Follow-up of Malignancies in Transplanted Patients
Enrollment Status: Completed
Publish Date: October 26, 2017
Intervention Type: Drug, Other
View 2 Less Clinical Trials

128 Total Publications

A human pan-disease blood atlas of the circulating proteome.
A human pan-disease blood atlas of the circulating proteome.
Journal: Science (New York, N.Y.)
Published: October 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Enblad's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile